The U.S. Food and Drug Administration Will Use GeneGo's MetaCore for 'OMIC's' Research and Reviewing of Genomics Data
Posted on: Monday, 10 October 2005, 09:00 CDT
ST. JOSEPH, Mich., Oct. 10 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Food and Drug Administration (FDA) have licensed MetaCore for "OMIC's" research and reviewing of genomics data. GeneGo and the FDA will also integrate MetaCore with ArrayTrack and make it available for FDA researchers, http://www.fda.gov/nctr/science/centers/toxicoinformatics/ArrayTrack/
The MetaCore platform allows scientists to concurrently visualize, map and network multiple types of data including gene expression, SiRNAi, proteomic, metabolomic, SAGE and SNP data, both from pre-clinical discovery and clinical studies.
"High throughput (HT) experimentation is increasingly important for life science research, and HT data is now included in many new drug applications submissions. The analysis of such complex datasets requires novel systems biology tools, such as MetaCore," said Dr Tatiana Nikolskaya, founder and CSO of GeneGo Inc. "One important issue in FDA submissions is compatibility and cross-referencing of multiple types of pre-clinical and clinical data, which are collected at different times by different research groups. MetaCore offers both a functional framework and analytical engine for this."
"Working with the FDA is very important for GeneGo and we are very pleased to announce this relationship," said Julie Bryant, Vice President of Business Development at GeneGo. "Since MetaCore is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will be also used on the regulatory side as well."
GeneGo has assembled the world largest manually curated database of human biology and medicinal chemistry, which includes genes, proteins, natural ligands, metabolites, drugs and diseases from millions of literature findings.
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 2.5, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com/.
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc. About ArrayTrack
ArrayTrack provides an integrated solution for managing, analyzing, and interpreting microarray gene expression data. Specifically, ArrayTrack is MIAME (Minimum Information About A Microarray Experiment) supportive for storing both microarray data and experiment parameters associated with a pharmaco- or toxico- genomics study. Many statistical and visualization tools are available with ArrayTrack. ArrayTrack also provides a rich collection of functional information about genes, proteins and pathways for biological interpretation. The primary emphasis of ArrayTrack is the direct linking of analysis results with functional information for facilitating the interaction between the choice of analysis methods and the biological relevance of analysis results. Using ArrayTrack, user can easily select a statistical method applied to a stored microarray data to determine a list of differentially expressed genes and the gene list can be directly linked to pathways and gene ontology for functional analysis.
GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
Source: PRNewswire
Related Articles
- GeneGo Licenses MetaCore to Proteostasis Therapeutics
- Researchers Identify Key Gene That Protects Against Leukemia
- The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
- GlaxoSmithKline Collaborates With National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
- DSPCon Wins Four New NASA Contracts for Advanced Data Acquisition and Analysis Systems
- 2007 Analysis and Research Report on China Solar Grade Multicrystal Silicon Industry
- Dendreon Receives Complete Response Letter From FDA for Provenge(R) Biologics License Application
- Molecular Devices Introduces SoftMax(R) Pro 5 Advanced Data Acquisition and Analysis Software
- QuestionPro Adds Rich Features to Online Survey Service; Sophisticated Data-Collection and Analysis Tools Enable More Accurate Market Research and Increased Customer Insight
- US Researchers Discover Fat Gene
User Comments (0)


RSS Feeds